Aventis Menactra May Get CDC Endorsement For Teens And College Freshmen
This article was originally published in The Pink Sheet Daily
Executive Summary
The meningococcal conjugate vaccine will be provided as catch up to 11- to 18-year-olds depending on supply. CDC projects the cost of the vaccine, which could be approved this year, at $80 per dose.
You may also be interested in...
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar
Menactra May Require More Data For Approval, Advisory Committee Chair Says
"There are a number of issues" related to the meningococcal conjugate vaccine, committee chair Overturf tells National Vaccine Advisory Committee. Sanofi-Aventis says it has not submitted any additional data to FDA on Menactra.